BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 27606694)

  • 1. Utility of flow cytometry studies in the management of patients with multiple myeloma.
    Paiva B; Merino J; San Miguel JF
    Curr Opin Oncol; 2016 Nov; 28(6):511-517. PubMed ID: 27606694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
    Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
    Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
    Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparameter immunophenotyping by flow cytometry as a diagnostic tool in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Carulli G; Ottaviano V; Cannizzo E; Giuntini S; Manetti C; Ciancia EM; Azzarà A
    Clin Ter; 2012; 163(5):387-92. PubMed ID: 23099966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.
    Paiva B; Almeida J; Pérez-Andrés M; Mateo G; López A; Rasillo A; Vídriales MB; López-Berges MC; Miguel JF; Orfao A
    Cytometry B Clin Cytom; 2010 Jul; 78(4):239-52. PubMed ID: 20155853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current applications of multiparameter flow cytometry in plasma cell disorders.
    Jelinek T; Bezdekova R; Zatopkova M; Burgos L; Simicek M; Sevcikova T; Paiva B; Hajek R
    Blood Cancer J; 2017 Oct; 7(10):e617. PubMed ID: 29053157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
    Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
    Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparameter Flow Cytometry Identification of Neoplastic Subclones: A New Biomarker in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
    Tarín F; López-Castaño F; García-Hernández C; Beneit P; Sarmiento H; Manresa P; Alda O; Villarrubia B; Blanes M; Bernabéu J; Amorós C; Sánchez-Sánchez S; Fernández-Miñano C; De Paz F; Verdú-Belmar J; Marco P; Matutes E
    Acta Haematol; 2019; 141(1):1-6. PubMed ID: 30428459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
    Paiva B; van Dongen JJ; Orfao A
    Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multiple myeloma immunophenotyping: method validation].
    Vergnolle I; Rieu JB; Avet-Loiseau H; Corre J; Vergez F
    Ann Biol Clin (Paris); 2019 Apr; 77(2):197-217. PubMed ID: 30998199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
    Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
    Cytometry B Clin Cytom; 2015 Mar; 88(2):101-9. PubMed ID: 25399680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
    Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
    Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
    Yuan CM; Stetler-Stevenson M
    Semin Hematol; 2011 Jan; 48(1):32-8. PubMed ID: 21232656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Myeloma Minimal Residual Disease.
    Paiva B; García-Sanz R; San Miguel JF
    Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review].
    Yu Q; Shi JM; Tao Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):961-964. PubMed ID: 28641668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients.
    Riebl V; Dold SM; Wider D; Follo M; Ihorst G; Waldschmidt JM; Jung J; Rassner M; Greil C; Wäsch R; Engelhardt M
    Front Oncol; 2021; 11():708231. PubMed ID: 34485145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.
    Paiva B; Vidriales MB; Pérez JJ; Mateo G; Montalbán MA; Mateos MV; Bladé J; Lahuerta JJ; Orfao A; San Miguel JF; ;
    Haematologica; 2009 Nov; 94(11):1599-602. PubMed ID: 19880781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells.
    Mack EKM; Hartmann S; Ross P; Wollmer E; Mann C; Neubauer A; Brendel C; Hoffmann J
    Ann Hematol; 2022 Apr; 101(4):811-824. PubMed ID: 35106639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.